Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.44 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.42 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117353 | 1.00 | FAAH (0.58) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL76219 | 1.00 | FAAH (0.58) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL75691 | 1.00 | FAAH (0.58) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL74738 | 1.00 | FAAH (0.58) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL76255 | 1.00 | FAAH (0.58) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Hydrochloric Acid SCHEMBL17394702 | 0.98 | FAAH (0.56) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL28918314 | 0.94 | FAAH (0.51) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Phosphoric Acid SCHEMBL4609086 | 0.94 | MEN1 (0.51) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL29013598 | 0.94 | FAAH (0.51) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL19847081 | 0.94 | FAAH (0.51) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214456-A1 | Lkktet and/or Lkktnt Peptide Compositions and Methods | REGENERX BIOPHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | claimed |
| EP-1896050-A2 | LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS AND METHODS | Regenerx Biopharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006138709-A2 | LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS AND METHODS | REGENERX BIOPHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| US-10772885-B2 | Composition for treating ocular diseases and methods of usage and making | REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2020-09-15 | — | — | US | disclosed |
| EP-3515444-A1 | COMPOSITION FOR TREATING OCULAR DISEASES AND METHODS OF USAGE AND MAKING | Reyoung (Suzhou) Biology Science & Technology Co., Ltd (CN) | 2019-07-31 | — | — | EP | disclosed |
| US-20190224194-A1 | COMPOSITION FOR TREATING OCULAR DISEASES AND METHODS OF USAGE AND MAKING | REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
| US-10004785-B2 | LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized | REGENERX BIOPHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3326647-A1 | LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS WHICH ARE LYOPHILIZED OR IN A FORM CAPABLE OF BEING LYOPHILIZED | Regenerx Biopharmaceuticals, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2018054077-A1 | COMPOSITION FOR TREATING OCULAR DISEASES AND METHODS OF USAGE AND MAKING | REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD (CN) | 2018-03-29 | — | — | WO | disclosed |
| US-20180028619-A1 | LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS WHICH ARE LYOPHILIZED OR IN A FORM CAPABLE OF BEING LYOPHILIZED | REGENERX BIOPHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9821030-B2 | LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized | REGENERX BIOPHARMACEUTICALS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| EP-1904080-A1 | LKKTET AND/OR LKKTNT COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE | Regenerx Biopharmaceuticals, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1896050-A2 | LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS AND METHODS | Regenerx Biopharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1295591-B1 | HAIR GROOMING PREPARATION | SHISEIDO CO LTD (JP) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006138708-A1 | LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS WHICH ARE LYOPHILIZED OR IN A FORM CAPABLE OF BEING LYOPHILIZED | REGENERX BIOPHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138709-A2 | LKKTET AND/OR LKKTNT PEPTIDE COMPOSITIONS AND METHODS | REGENERX BIOPHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138707-A1 | LKKTET AND/OR LKKTNT COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE | REGENERX BIOPHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-7147843-B2 | Hydrophobic polyether urethane C23+ endcapped (especially from 2-decyltetradecanol) and cationic surfactant; also cleaning agent containing the modified polymer and anionic surfactant and/or ampholytic surfactant. | SHISEIDO COMPANY, LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| EP-1295591-A1 | HAIR GROOMING PREPARATION | SHISEIDO COMPANY LIMITED (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-20030012761-A1 | Hair grooming preparation | SHISEIDO COMPANY, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012761-A1 | Hair grooming preparation | SHH, ITCH, SPAST | FAAH 44/4885MEN1 3505/4885KMT2A 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.